Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377211 | 1.00 | ALOX15 (0.36) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL3381913 | 0.87 | OTC (0.35) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL3381907 | 0.87 | OTC (0.35) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL28986669 | 0.85 | ALOX15 (0.37) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL19729337 | 0.84 | ALOX15 (0.37) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL288819 | 0.83 | NOS2 (0.38) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL160690 | 0.83 | NOS2 (0.38) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL196827 | 0.83 | NOS2 (0.38) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL2673036 | 0.83 | ALOX15 (0.36) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL2673040 | 0.83 | ALOX15 (0.36) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | disclosed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | ALOX15 442/4885MEN1 4763/4885KMT2A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.